All In Biotech

Drug Trial Radar · NCT02158858

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)

Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

336

Actual

Start

Jul 16, 2014

Primary completion

Jan 9, 2025

Study completion Jan 9, 2025

Sponsor

Lead sponsor
Constellation PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
The Leukemia and Lymphoma Society
First posted
Jun 9, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 Part: This was an open-label, sequential dose escalation study of pelabresib (CPI-0610) in patients who had previously been treated for Acute Leukemia, Myelodysplastic/Myeloproliferative Neoplasms. Phase 2 Part: This was an open-label study of pelabresib (CPI-0610), administered with and without Ruxolitinib, in patients diagnosed with Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia). Pelabresib (CPI-0610) was a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

Conditions

  • Myelofibrosis
  • Leukemia, Myelocytic, Acute
  • Myelodysplastic/Myeloproliferative Neoplasm
  • Myelodysplastic Syndrome (MDS)
  • Preleukemia
  • Primary Myelofibrosis
  • Myeloproliferative Disorders
  • Bone Marrow Disease
  • Hematological Disease
  • Precancerous Conditions
  • Neoplasms
  • Leukemia
  • Neoplasms by Histologic Type
  • Essential Thrombocytosis

Interventions

  • PelabresibDrug

    CPI-0610 was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)

  • RuxolitinibDrug

    Ruxolitinib was given orally, twice daily (BID), on a continuous basis for 21 consecutive days of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Frequency of Dose-limiting Toxicities (DLTs)Time frame: Up to 21 days
  2. Phase 2 (Cohorts 1B, 2B, and Arm 3): Number of Participants With Splenic Response Rate (SVR35) at Week 24Time frame: Week 24 (Cycle 9 Day 1)
  3. Phase 2 (Cohorts 1A and 2A): Number of Participants Enrolled as Transfusion Dependent (TD) With Conversion Rate From Red Blood Cell (RBC) Transfusion Dependence (TD) to Transfusion Independence (TI)Time frame: Any 12 consecutive weeks (rolling window) during active treatment with pelabresib (CPI-0610), from first dose through treatment discontinuation (up to approximately 8 years for Phase II)
  4. Phase 2 (Arm 4): Number of Participants With Complete Hematological Response (CHR) RateTime frame: Over 2 consecutive cycles (rolling window) (1 cycle = 21 days)

Locations

48 sites in 9 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • UCLA Medical Center

    Los Angeles, California

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • Northwestern University - Lurie Comprehensive Cancer Center

    Chicago, Illinois

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts

  • University of Michigan Medical Center

    Ann Arbor, Michigan

  • Washington University School of Medicne Neuromuscular Division Department of Neurology Research

    St Louis, Missouri

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • ICAHN School of Medicine at Mount Sinai

    New York, New York

  • Weill Medical College and New York Presbyterian Hospital

    New York, New York

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Froedtert & Medical College of Wisconsin

    Milwaukee, Wisconsin

  • ZNA Stuyvenberg Antwerpen

    Antwerp, Belgium

  • UZ Leuven - Campus Gasthuisberg

    Leuven, Viaams Braban, Belgium

  • AZ Sint-Jan Burgge-Oostende AV- Campus Sint-Jan

    Bruges, West-Vlaanderen, Belgium

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • St. Paul's Hospital

    Vancouver, British Columbia, Canada

  • Juravinski Cancer Centre

    Hamilton, Ontario, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • CHU - Hopital Saint Louis - Centre D'Investigations Clinique

    Paris, France

  • Institut de cancérologie du Gard - Hematologie clinique

    Nîmes, Gard, France

  • CHRU de Lille - Hopital Claude Huriez

    Toulouse, Haute-Garonne, France

  • CHRU de Lille - Hopital Claude Huriez - Maladies du Sang

    Lille, Hauts-de-France, France

  • Institut Gustave Roussy

    Villejuif, Île-de-France Region, France

  • Universitätsklinikum Bonn

    Bonn, North Rhine-Westphalia, Germany

  • Universitätsklinikum Leipzig AöR

    Leipzig, Saxony, Germany

  • Azienda Ospedaliero-Universitaria Careggi

    Florence, Italy

  • AOU Maggiore della Carità

    Novara, Italy

  • Institue of Hematology "L. and A. Seràgnoli"

    Bologna, Emilia-Romagna, Italy

  • Servizio Sanitario Regionale Emilia-Romagna - Azienda Unita Sanitaria Locale (AUSL) di Rimini - Ospedale Infermi di Rimini

    Rimini, Emilia-Romagna, Italy

  • AOU S.Martino, IRCCS, IST-Istituto Nazionale Ricerca Sul Can

    Genoa, Liguria, Italy

  • Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda

    Milan, Lombardy, Italy

  • IRCCS Policlinico San Matteo, Università degli studi di Pavi

    Pavia, Lombardy, Italy

  • Ospedale di Circolo, PO Varese, AO Ospedale di Circolo e Fon

    Varese, Lombardy, Italy

  • Maastricht University Medical Center

    Maastricht, Limburg, Netherlands

  • VUmcResearch B.V.

    Amsterdam, North Holland, Netherlands

  • Erasmus Universitair Medisch Centrum Rotterdam

    Rotterdam, South Holland, Netherlands

  • Instytut Hematologii i Transfuzjologii w Warszawie

    Warsaw, Masovian Voivodeship, Poland

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Pomeranian Voivodeship, Poland

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.